Suzanne George
苏珊娜·乔治
MD
Associate Professor of Medicine; Director, Sarcoma Center
👥Biography 个人简介
Suzanne George, MD is Associate Professor of Medicine at Harvard Medical School and Director of the Sarcoma Center at Dana-Farber Cancer Institute, where she leads an internationally recognized program in sarcoma and gastrointestinal stromal tumor clinical research. She is a world authority on GIST, with particular expertise in wild-type and SDH-deficient GIST—rare subtypes lacking KIT/PDGFRA mutations—and in the clinical development of second- and later-line targeted therapies for advanced GIST. Dr. George has served as a lead US investigator in pivotal trials of sunitinib, regorafenib, and ripretinib in GIST and has contributed foundational translational work on the molecular biology of succinate dehydrogenase-deficient GIST, pediatric GIST, and Carney triad. She is a past chair of the CTOS Scientific Program Committee and a co-author of NCCN guidelines for GIST. She has authored over 180 peer-reviewed publications.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Sunitinib as Second-Line GIST Therapy
Served as a principal US investigator in the pivotal phase III trial of sunitinib versus placebo in imatinib-resistant or intolerant advanced GIST, establishing sunitinib as the global second-line standard of care and defining genotype-specific response patterns by KIT exon mutation status.
Wild-Type and SDH-Deficient GIST Biology
Led foundational clinical and molecular studies characterizing SDH-deficient GIST and its associated syndromes (Carney triad, Carney-Stratakis syndrome, pediatric GIST), identifying hypermethylation-driven silencing of SDHC as a key mechanism and establishing this entity as a biologically and therapeutically distinct GIST subtype.
Ripretinib INVICTUS and INTRIGUE Trials
Led US participation in the INVICTUS (4th-line) and INTRIGUE (2nd-line vs sunitinib) phase III trials of ripretinib in advanced GIST, contributing to the approval and further clinical characterization of this switch-control KIT/PDGFRA inhibitor.
Translational Biomarker Research in GIST
Conducted translational studies correlating KIT/PDGFRA genotype with response to imatinib and sunitinib, and explored circulating tumor DNA as a minimally invasive biomarker for monitoring resistance evolution in advanced GIST, informing personalized treatment sequencing.
Representative Works 代表性著作
Sunitinib Malate for the Treatment of Imatinib-Refractory or Intolerant GIST
Oncologist (2011)
Comprehensive analysis of sunitinib clinical activity and genotype-response correlations in imatinib-refractory GIST, establishing KIT exon 9 mutation as a predictor of differential benefit from second-line therapy.
SDH-Deficient GIST: Characteristic Clinicopathologic, Immunohistochemical, and Molecular Features
American Journal of Surgical Pathology (2011)
Defining clinicopathological and molecular characterization of SDH-deficient GIST, establishing diagnostic criteria and distinguishing features from KIT/PDGFRA-mutant GIST.
Phase III INTRIGUE Trial: Ripretinib versus Sunitinib in Second-Line Advanced GIST
Journal of Clinical Oncology (2022)
Phase III trial comparing ripretinib and sunitinib as second-line therapy in advanced GIST, providing important data on the comparative efficacy of broad-spectrum versus sequential KIT inhibition and informing treatment sequencing strategies.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-04-06 | All information from publicly available academic sources
Related Experts 相关专家
Sebastian Bauer
University Hospital Essen (Universitätsklinikum Essen)
Marcia S. Brose
Sidney Kimmel Cancer Center, Thomas Jefferson University
Lori J. Wirth
Massachusetts General Hospital, Harvard Medical School
Steven I. Sherman
MD Anderson Cancer Center, University of Texas
关注 苏珊娜·乔治 的研究动态
Follow Suzanne George's research updates
留下邮箱，当我们发布与 Suzanne George（Dana-Farber Cancer Institute / Harvard Medical School）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment